ARTICLE | Product Development
Mirati data underscore KRAS opportunity in colorectal cancer
Mirati’s latest KRAS inhibitor data point to a potential efficacy advantage in colorectal cancer
September 19, 2021 1:58 PM UTC
Colorectal cancer is the new battleground for the most advanced KRAS inhibitors, and Mirati’s latest data from ESMO leave the company in a very competitive position going into registrational studies.
During a poster session at the European Society of Medical Oncology (ESMO) congress on Sunday, Mirati Therapeutics Inc. (NASDAQ:MRTX) reported a monotherapy metastatic colorectal cancer win for its KRAS G12C inhibitor adagrasib, and found combination with EGFR inhibitor cetuximab is potentially synergistic in the Phase I/II KRYSTAL-1 study...